Prof. Dr. Abdullah Sakin
Is this your profile? Claim it and verify your details.
Claim profileThe CV on this page was translated automatically from its original language. See the original
Person ↔ Disease
Which diseases does this doctor work on?
-
Lung Neoplasms 19 publicationsSource: OpenAlex / PubMed MeSHView publications
- Carcinoma, Non-Small-Cell Lung 13 publications
- Colorectal Neoplasms 13 publications
- Stomach Neoplasms 12 publications
- Breast Neoplasms 12 publications
- Rectal Neoplasms 6 publications
- Esophageal Neoplasms 5 publications
- Colonic Neoplasms 4 publications
- Liver Neoplasms 4 publications
- Adenocarcinoma 3 publications
- Urinary Bladder Neoplasms 3 publications
- Bone Neoplasms 3 publications
- Carcinoma, Renal Cell 3 publications
- Esophageal Squamous Cell Carcinoma 3 publications
- Neoplasms 2 publications
- Carcinoma, Transitional Cell 2 publications
- Leiomyosarcoma 2 publications
- Neuroendocrine Tumors 2 publications
- Neoplasms, Second Primary 2 publications
- Kidney Neoplasms 2 publications
- Carcinoma, Ductal, Breast 2 publications
- Obesity 2 publications
Person ↔ Disease
Which topics does this doctor work on?
Medical areas of interest the doctor lists on their own profile on the institution’s website. Source: medipol.com.tr.
- Personalised cancer treatment
- Targeted (“smart drug”) therapy
- Chemotherapy
- Hormone therapy
- Immunotherapy
- Targeted therapies
- Monoclonal antibodies
- Interferon and interleukin
- Adoptive immunotherapy
- Intraperitoneal / intrapleural / intrathecal therapy
CV
Education and experience
Prof. Abdullah Sakin studied medicine at Uludağ University Faculty of Medicine from 2001 to 2007, qualifying as a medical doctor. He completed his specialty training in internal medicine at Istanbul Haseki Training and Research Hospital between 2008 and 2012 and then, with the aim of specialising in oncology, successfully completed subspecialty training in medical oncology at Istanbul Okmeydanı Training and Research Hospital between 2015 and 2018.
Prof. Sakin began his academic career in 2018 as Head of the Division of Medical Oncology and a faculty member at Yüzüncü Yıl University Faculty of Medicine, and was awarded the title of Associate Professor in 2020. In 2021 he joined the Department of Medical Oncology at Prof. Dr. Cemil Taşcıoğlu City Hospital as a Clinical Educator, playing an active role in both clinical care and specialty training. He now continues his academic work and clinical practice with the title of Professor.
Prof. Sakin focuses on the diagnosis and treatment of all solid tumours, including lung cancer, breast cancer, gastrointestinal cancers (particularly gastric, colon and rectal cancer), urological cancers (prostate, kidney and bladder cancer), gynaecological cancers (cervical, uterine and ovarian cancer), head and neck cancers and malignant melanoma. In his clinical practice he makes effective use of targeted therapies, immunotherapies and personalised cancer treatment approaches alongside conventional chemotherapy.
With more than 200 scientific articles published in respected national and international journals, as well as books and book chapters, Prof. Sakin also takes an active part in multicentre clinical trials and makes significant contributions to research on cancer treatment. A member of the Turkish Society of Medical Oncology, the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO), he continues to contribute to the literature, particularly through his work on lung, breast and gastrointestinal cancers.
Combining scientific knowledge with clinical experience, Prof. Sakin aims to provide his patients with up-to-date, evidence-based and individualised treatment, using the most advanced options that modern oncology offers to improve their quality of life and survival.
Experience
- 2022Private Medipol Bahçelievler Hospitalmedipol.com.tr
- 2021 - 2021Prof. Dr. Cemil Taşcıoğlu City HospitalClinical Educator, Department of Medical Oncology – Associate Professor
- 2021 - 2021Prof. Dr. Cemil Taşcıoğlu City Hospital, Clinical Educator, Department of Medical Oncologymedipol.com.tr
- 2020 - 2021Yüzüncü Yıl University Faculty of Medicine, Head of the Division of Medical Oncology, Associate Professormedipol.com.tr
- 2020 - 2021Yüzüncü Yıl University Faculty of MedicineHead of the Division of Medical Oncology – Associate Professor
- 2018 - 2021Yüzüncü Yıl University Faculty of MedicineHead of the Division of Medical Oncology, Lecturer
- 2018 - 2021Lecturer – Yüzüncü Yıl University Faculty of Medicine, Head of the Division of Medical Oncologymedipol.com.tr
- 2015 - 2018University of Health Sciences, Okmeydanı Training and Research Hospital, Subspecialty Fellow, Department of Medical Oncologymedipol.com.tr
- 2015 - 2018University of Health Sciences, Okmeydanı Training and Research HospitalSubspecialty Fellow, Department of Medical Oncology
- 2012 - 2015Kanuni Sultan Süleyman Training and Research Hospital, Specialist in Internal Medicinemedipol.com.tr
- 2012 - 2015Kanuni Sultan Süleyman Training and Research HospitalSpecialist in Internal Medicine
- 2008 - 2012Haseki Training and Research HospitalResident, Department of Internal Medicine
- 2006 - 2008General Practitioner, Kızıltepe No. 3 Primary Health Care Centremedipol.com.tr
Education
- 2018Istanbul Okmeydanı Training and Research Hospital, Medical Oncologymedipol.com.tr
- 2018Istanbul Okmeydanı Training and Research Hospital, Medical Oncology, Istanbul Okmeydanı Training and Research Hospital, Medical Oncologymedipol.com.tr
- 2012Istanbul Haseki Training and Research Hospital, Internal Medicine, Istanbul Haseki Training and Research Hospital, Internal Medicinemedipol.com.tr
- 2012Istanbul Haseki Training and Research Hospital, Internal Medicinemedipol.com.tr
- 2007Uludağ University Faculty of Medicine, Faculty of Medicine, Uludağ University Faculty of Medicine, Faculty of Medicinemedipol.com.tr
- 2007Uludağ University Faculty of Medicine, Faculty of Medicinemedipol.com.tr
Trust
Where does this information come from?
The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.
- SpecialtyInternal Medicine, Medical Oncologymedipol.com.trFrom source
- InstitutionMedipol Bahçelievler Üniversite Hastanesimedipol.com.trFrom source
- Area of workLung NeoplasmsExtracted from 19 publications · Model version —From source
- Publications247 publicationsOpenAlexFrom source
- LanguagesEnglishmedipol.com.trFrom source
- Last synchronised4 November 2026 20:17https://medipol.com.tr/doktorlarimiz/profdr-abdullah-sakinmedipol.com.tr
Scientific work
Publications on Lung Neoplasms
-
Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study
Clinical Medicine Insights Oncology, 2026
DOI 10.1177/11795549261445290 PMID 42131419 Open-access full textSource: OpenAlex
-
The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study
Medicina, 2026
DOI 10.3390/medicina62010214 PMID 41597500 Open-access full textSource: OpenAlex
-
Real-world practices in RAS wild-type metastatic colorectal cancer patients treated with targeted agents in the first-line a nationwide onco-colon Turkey registry
Anadolu Kliniği Tıp Bilimleri Dergisi, 2026
DOI 10.21673/anadoluklin.1675424 Open-access full textSource: OpenAlex
-
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis
Medicina, 2026
DOI 10.3390/medicina62050984 PMID 42195237 Open-access full textSource: OpenAlex
-
Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study
BMC Cancer, 2026
DOI 10.1186/s12885-026-15725-9 PMID 41691201 Open-access full textSource: OpenAlex
-
Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study
Discover Oncology, 2026
DOI 10.1007/s12672-026-04842-3 PMID 41870760 Open-access full textSource: OpenAlex
-
Perioperative FLOT versus Definitive 50.4 Gy Chemoradiotherapy in Siewert II Esophagogastric Junction Adenocarcinoma: A Multicenter Retrospective Cohort Study
Cancer Management and Research, 2026
DOI 10.2147/cmar.s583473 PMID 42038552 Open-access full textSource: OpenAlex
-
Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study
Cancers, 2026
DOI 10.3390/cancers18121979 PMID 42352512 Open-access full textSource: OpenAlex
-
Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study
BMC Cancer, 2026
DOI 10.1186/s12885-026-16868-5 Open-access full textSource: OpenAlex
-
Resection and pathological response after neoadjuvant nivolumab plus chemotherapy for lung cancer in a Turkish Oncology Group (TOG) real-world study
Research Square, 2026
DOI 10.21203/rs.3.rs-11204389/v1 Open-access full textSource: OpenAlex